Fate Therapeutics (FATE) Tops Q3 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• World Acceptance (WRLD) Tops Q1 EPS by 168c
• ArcelorMittal Q2 2026 analyst consensus: $2.04B EBITDA expected